Table 1 Patient demographics and baseline disease characteristicsa
Erivance BCC (N = 104) | EAS (N = 119) | ||||||
|---|---|---|---|---|---|---|---|
laBCC | mBCC | laBCC | mBCC | ||||
BCCNS (n = 22) | Non-BCCNS (n = 49) | Non-BCCNS (n = 33) | BCCNS (n = 12) | Non-BCCNS (n = 50) | BCCNS (n = 7) | Non-BCCNS (n = 50) | |
Median age, years (range) | 47 (21–71) | 67 (38–101) | 62 (38–92) | 52 (26–79) | 67 (40–92) | 58 (37–71) | 63 (24–100) |
Female, n (%) | 10 (45) | 22 (45) | 9 (27) | 6 (50) | 13 (26) | 3 (43) | 9 (18) |
WCBP, n (%) | 3 (33) | 1 (2) | 2 (6) | 4 (33) | 2 (4) | 1 (14) | 1 (2) |
ECOG PS, n (%) | |||||||
0–1 | 22 (100) | 44 (90) | 32 (97) | 12 (100) | 46 (92) | 7 (100) | 45 (90) |
2 | 0 | 5 (10) | 1 (3) | 0 | 4 (8) | 0 | 5 (10) |
Target lesions, n (%) | |||||||
1 | 13 (59) | 35 (71) | 9 (27) | 4 (33) | 30 (60) | 4 (57) | 20 (40) |
2 | 4 (18) | 8 (16) | 4 (12) | 2 (17) | 11 (22) | 0 | 10 (20) |
≥3 | 5 (23) | 6 (12) | 20 (61) | 6 (50) | 9 (18) | 3 (43) | 20 (40) |
Prior treatment, n (%) | |||||||
Surgery | 21 (96) | 41 (84) | 32 (97) | 12 (100) | 45 (90) | 7 (100) | 47 (94) |
Radiotherapy | 1 (5) | 21 (43) | 19 (58) | 1 (8) | 19 (38) | 2 (29) | 33 (66) |
Systemic therapy | 5 (23) | 3 (6) | 10 (30) | 2 (17) | 9 (18) | 2 (29) | 18 (36) |
Surgery contraindicated, n (%) | 18 (82) | 25 (51) | NA | 7 (58) | 28 (56) | NA | NA |